Net Debt Summary of Azitra, Inc.

Azitra, Inc.'s latest annual net debt in 2023 was -910.04 Thousand USD , down -121.49% from previous year.
Azitra, Inc.'s latest quarterly net debt in 2024 Q2 was -80.42 Thousand USD , up 96.34% from previous quarter.
Azitra, Inc. reported annual net debt of 4.23 Million USD in 2022, up 160.06% from previous year.
Azitra, Inc. reported annual net debt of -7.05 Million USD in 2021, down 0.0% from previous year.
Azitra, Inc. reported quarterly net debt of -2.19 Million USD for 2024 Q1, down -141.38% from previous quarter.
Azitra, Inc. reported quarterly net debt of -3.44 Million USD for 2023 Q3, up 35.06% from previous quarter.

Annual Net Debt Chart of Azitra, Inc. (2023 - 2021)

Name	Net Debt	Net Debt Difference
AIM ImmunoTech Inc.	-4.94 Million USD	81.593%
Ampio Pharmaceuticals, Inc.	-3.81 Million USD	76.146%
Armata Pharmaceuticals, Inc.	106.84 Million USD	100.852%
Actinium Pharmaceuticals, Inc.	-74.56 Million USD	98.78%
Can-Fite BioPharma Ltd.	-4.23 Million USD	78.527%
Chromocell Therapeutics Corporation	1.17 Million USD	177.629%
Calidi Biotherapeutics, Inc.	5.18 Million USD	117.545%
CEL-SCI Corporation	9.42 Million USD	109.655%
iBio, Inc.	-9.75 Million USD	90.666%
Lineage Cell Therapeutics, Inc.	-32.49 Million USD	97.199%
MAIA Biotechnology, Inc.	-7.15 Million USD	87.273%
Matinas BioPharma Holdings, Inc.	-1.28 Million USD	28.958%
Navidea Biopharmaceuticals, Inc.	438.44 Thousand USD	307.562%
NovaBay Pharmaceuticals, Inc.	-390 Thousand USD	-133.344%
NanoViricides, Inc.	-4.79 Million USD	81.032%
Oragenics, Inc.	-3.17 Million USD	71.299%
BiomX Inc.	-772 Thousand USD	-17.881%
BiomX Inc.	-772 Thousand USD	-17.881%
Protalix BioTherapeutics, Inc.	2.64 Million USD	134.38%
Palatin Technologies, Inc.	-8.93 Million USD	89.817%
Scorpius Holdings, Inc.	13.85 Million USD	106.567%